KILIMANJARO: THE Moshi-based KCMC Zonal Referral Hospital (KCMC ZRH) has achieved a significant medical milestone after ...
Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
Newspoint on MSN
Enlarged prostate symptoms: These 5 signs after the age of 40 are a warning sign for men ...
Prostate Enlargement Treatment: Prostate problems are increasing rapidly in men. Let us tell you which major signs should not be ignored after 40 and when should you consult a doctor? What are the ...
At 77 years old, Tyson Johnson has been in treatment for metastatic prostate cancer for more than 20 years. “I’m the healthiest dead man you’ve ever seen,” the Carthage resident said jokingly as he ...
Early trials of the drug VIR-5500 showed it shrinking tumours in some patients A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication ...
SAN FRANCISCO -- Adding hormone therapy to postoperative radiotherapy did not improve overall survival (OS) for most men with prostate cancer, according to a meta-analysis of individual patient data.
JACKSONVILLE, Fla. – Prostate cancer is the most common cancer in men in the U.S. after skin cancer, but it is often slow-growing and highly treatable. Now there is a minimally invasive treatment, ...
Friends of Joe Biden are said to be concerned about the former president as he battles an aggressive form of prostate cancer, according to reports. While aides told how he is doing well, others have ...
Radiotherapy trial uses ‘homing device’ to seek out cancers all around the body Laura Donnelly is the Health Editor for The Telegraph, leading award-winning coverage on the NHS, medical science ...
As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW Investments has stepped in with $100 million to bankroll the launch. The nine-figure ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果